 BOSTON, Sept. 09, 2021 GLOBE NEWSWIRE -- Decibel Therapeutics Nasdaq: DBTX, a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that the U.S. Food and Drug Administration FDA has granted both Orphan Drug Designation and Rare Pediatric Disease Designation for the companys lead gene therapy product candidate, DB-OTO, for the treatment of patients with otoferlin-related congenital hearing loss. 